证券代码：603717 证券简称：天域生物 公告编号：2025-043 天域生物科技股份有限公司 1 案件所处的仲裁阶段：已裁决，收到上海仲裁委员会《裁决书》 上市公司所处的当事人地位：仲裁申请人 涉案金额：43,295,330.52 元及本案仲裁费用 是否会对上市公司损益产生负面影响：本次《裁决书》能否顺利执行以 及裁定金额到账时间等存在重大不确定性，本次仲裁案件对公司本期利 润或期后利润的具体影响，将依据《裁决书》的履行和实际执行情况以 及审计机构对财务报表的审计确认情况为准。敬请广大投资者谨慎决策， 注意投资风险。 生因未如期履行业绩补偿义务一案提起仲裁申请。2023 年 08 月 30 日，公司收到 上海仲裁委员会送达的"（2023）沪仲案字第 4766 号争议仲裁案"《仲裁通知 书》，具体内容详见公司于 2023 年 08 月 31 日在上海证券交易所官方网站和指定 信息披露媒体上发布的《关于业绩补偿事项申请仲裁的公告》（公告编码：2023- 093）。 二、本次仲裁裁决情况 近日，公司收到上海仲裁委员会送达的"（2023）沪仲案字第 4766 号争议 仲裁案"《裁决书》，裁决结果如下： 1、被申请 ...

2025 年 5 月养殖业务主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）现将 2025 年 5 月养殖业务 主要经营数据公告如下： 证券代码：603717 证券简称：天域生物 公告编号：2025-042 天域生物科技股份有限公司 二、特别提示 1、上述经营数据均未经审计，与定期报告披露的数据之间可能存在差异， 因此仅作为阶段性数据供投资者参考。 2、基于生猪市场价格大幅波动以及公司投苗节奏变化等因素影响，未来公 一、2025 年 5 月养殖行业主要经营数据 2025 年 5 月，公司销售生猪 2.48 万头，销售收入 4,038.75 万元，环比变动分 别为-29.18%、-31.93%，同比变动分别为 5.26%、-0.63%。 2025 年 1-5 月，公司累计销售生猪 17.24 万头，同比上升 16.21%；累计销售 收入 27,404.81 万元，同比上升 21.27%。 2025 年 5 月末，公司生猪存栏 14.14 万头，同比上升 0.46%，环 ...

宁波富达：终止筹划重大资产重组事项 宁波富达(600724)公告，公司原计划以现金方式通过股权受让或增资方式取得宁波晶鑫电子材料有限 公司不少于45%股权，并保证上市公司拥有目标公司的表决权股权比例不低于51%。由于交易双方未 能就交易最终方案达成一致，经友好协商，各方同意终止进一步推进本次交易。终止本次重大资产重 组事项无需提交董事会、股东会审议。交易尚处于筹划阶段，未对上市公司现有生产经营活动、财务 状况和战略发展造成重大不利影响。公司承诺自公告披露之日起至少一个月内不再筹划重大资产重 组。 蓝黛科技：拟3411万元收购重庆台冠18%股权 2025.05. 09 5月9日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者 参考。 【品大事】 卧龙地产：证券简称变更为"卧龙新能" 卧龙地产(600173)公告，公司证券简称将自2025年5月15日起由"卧龙地产"变更为"卧龙新能"，公司 证券代码保持不变。 蓝黛科技(002765)公告，拟收购殷文俊、刘健、孙刚、崔颖合计持有的公司控股子公司重庆台冠18% 股权，转让价款为3411万元。本次股权收购完成后，公司将持有重庆台冠100 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

证券代码：603717 证券简称：天域生物 公告编号：2025-041 2025 年 4 月末，公司生猪存栏 13.32 万头，同比上升 3.38%，环比下降 4.80%。 天域生物科技股份有限公司 | 月份 | | 销售数量（万头） | | | 销售收入（万元） | 期末库存量 | | --- | --- | --- | --- | --- | --- | --- | | | | 当月 | 累计 | 当月 | 累计 | （万头） | | 年 2025 | 月 1 | 3.94 | 3.94 | 6,115.20 | 6,115.20 | 17.01 | | 2025 年 | 2 月 | 3.12 | 7.06 | 4,270.88 | 10,386.08 | 15.14 | | 年 2025 | 月 3 | 4.16 | 11.25 | 7,047.03 | 17,433.11 | 14.00 | | 2025 年 | 4 月 | 3.51 | 14.76 | 5,932.95 | 23,366.06 | 13.32 | 2025 年 4 月养殖业务主要经营数据公告 月度主要经营数据汇总如下： 本公司董事会 ...

天域生物（603717）公告，2025年4月公司销售生猪3.51万头，销售收入5932.95万元，环比变动分别 为-16.38%、-15.81%，同比变动分别为4.61%、25.66%。2025年1-4月，公司累计销售生猪14.76万头， 同比上升18.28%；累计销售收入2.34亿元，同比上升26.07%。2025年4月末，公司生猪存栏13.32万头， 同比上升3.38%，环比下降4.80%。 ...

锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址:上海市浦东新区银城中路 501 号上海中心 11、12 层 电话:021-20511000 传真:021-20511999 邮编:200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于天域生物科技股份有限公司 上海市锦天城律师事务所 关于天域生物科技股份有限公司 2024 年年度股东大会的 2024 年年度股东大会的法律意见书 法律意见书 致:天域生物科技股份有限公司 上海市锦天城律师事务所(以下简称"本所")接受天域生物科技股份有限 公司(以下简称"公司")委托,就公司召开 2024年年度股东大会(以下简称 "本次股东大会")的有关事宜,根据《中华人民共和国公司法》(以下简称"《公 司法》")《上市公司股东会规则》等法律、法规和其他规范性文件以及《天域 生物科技股份有限公司章程》(以下简称"《公司章程》")的有关规定,出具 本法律意见书。 为出具本法律意见书,本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定,严格履行 了法定职责,遵循了勤勉尽责和诚实 ...

证券代码：603717 证券简称：天域生物 公告编号：2025-040 天域生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 6 日 (二)股东大会召开的地点：上海市杨浦区国权北路 1688 号湾谷科技园 C4 幢二层 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 189 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 71,392,789 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 24.6057 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 (一)非累积投票议案 1、 议案名称：《2024 年度董事会工作报告》 审议结果：通过 表决情况： | 股东类型 | 同意 | | ...

证券代码：603717 证券简称：天域生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 登录新浪财经APP 搜索【信披】查看更多考评等级 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 持股5%以上股 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 225,272,371.07, representing a 6.68% increase compared to CNY 211,157,093.90 in the same period last year[4] - Net profit attributable to shareholders increased by 52.50% to CNY 13,768,228.59 from CNY 9,028,099.06 year-on-year[4] - Basic and diluted earnings per share rose by 52.73% to CNY 0.0475 from CNY 0.0311 in the same period last year[4] - Net profit for Q1 2025 was ¥27,095,976.56, representing a 46.4% increase from ¥18,520,621.51 in Q1 2024[17] - The net profit attributable to shareholders of the parent company was ¥13,768,228.59, up 52.5% from ¥9,028,099.06 in Q1 2024[18] Cash Flow - The net cash flow from operating activities was CNY 46,955,521.04, a significant improvement from a negative cash flow of CNY -14,786,979.09 in the previous year[4] - Cash inflow from operating activities totaled ¥307,826,073.15 in Q1 2025, slightly up from ¥302,933,679.53 in Q1 2024[20] - The net cash flow from operating activities was $46,955,521.04, a significant improvement compared to a negative cash flow of $14,786,979.09 in the previous period[21] - Total cash inflow from investing activities was $525,404.98, down from $16,604,563.63 in the prior period, indicating a decrease in investment returns[21] - Cash outflow for investing activities totaled $18,971,943.51, compared to $32,462,993.94 previously, reflecting a reduction in capital expenditures[21] - The net cash flow from financing activities was negative at $39,473,444.59, contrasting with a positive cash flow of $67,844,342.94 in the previous period[21] - Cash and cash equivalents at the end of the period stood at $89,356,979.46, down from $132,235,266.08 previously, indicating a decrease in liquidity[21] Assets and Liabilities - Total assets decreased by 5.03% to CNY 3,053,355,837.67 from CNY 3,214,984,288.09 at the end of the previous year[5] - The company's current assets totaled ¥1,331,315,032.87, down from ¥1,452,794,300.42, indicating a decrease of about 8.33%[13] - The company's total liabilities were ¥2,317,727,614.56, a reduction from ¥2,506,452,041.54, reflecting a decrease of approximately 7.53%[14] - The company's cash and cash equivalents stood at ¥154,661,388.37, compared to ¥178,048,527.26, showing a decline of around 13.14%[12] - Accounts receivable decreased to ¥315,903,186.86 from ¥391,229,321.24, marking a reduction of approximately 19.24%[12] - Inventory decreased to ¥202,900,702.90 from ¥223,765,533.14, indicating a decline of about 9.31%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,613[9] - Major shareholders include Luo Weiguo with 12.84% ownership and Shi Dongwei with 11.15% ownership, both having pledged a significant portion of their shares[9] - The company reported a total of 10 major shareholders, with the largest being 罗卫国, holding 37,251,829 shares[10] - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[11] Expenses - Total operating costs for Q1 2025 were ¥226,794,913.72, up 12.4% from ¥201,684,498.85 in Q1 2024[16] - Research and development expenses increased significantly to ¥4,320,459.41 in Q1 2025, compared to ¥1,624,358.50 in Q1 2024, reflecting a focus on innovation[16] - Financial expenses rose to ¥13,633,844.21 in Q1 2025, compared to ¥3,835,494.30 in Q1 2024, primarily due to increased interest expenses[16] Equity - The total equity attributable to shareholders of the parent company increased to ¥532,507,338.64 from ¥518,739,110.05 year-over-year[15] - The company reported a total equity of ¥735,628,223.11, up from ¥708,532,246.55 in the previous year[15] Other Information - The company will not apply new accounting standards starting from 2025, as per the announcement[22]